ARCA biopharma Retains Ladenburg Thalmann to Support Strategic Options Review
May 05 2022 - 4:15PM
ARCA biopharma, Inc. (Nasdaq: ABIO) today announced that it has
retained Ladenburg Thalmann & Co. Inc. to act as its financial
advisor.
In April 2022, the Board of Directors
established a Special Committee to explore and evaluate strategic
options for maximizing stockholder value. Potential strategic
alternatives that may be explored or evaluated as part of this
process include the potential for an acquisition, merger, business
combination or other strategic transaction involving the Company.
The Board has not set a timetable for the conclusion of this
review, nor has it made any decisions related to any further
actions or potential strategic options at this time. There can be
no assurance, however, that this process will result in any such
transaction.
About ARCA biopharmaARCA
biopharma is dedicated to developing genetically and other targeted
therapies for cardiovascular diseases through a precision medicine
approach to drug development. At present, ARCA is evaluating
options for development of its assets, including partnering and
other strategic options. For more information, please visit
www.arcabio.com.
Safe Harbor StatementThis press
release contains "forward-looking statements" for purposes of the
safe harbor provided by the Private Securities Litigation Reform
Act of 1995. These statements include, but are not limited to,
statements regarding potential strategic options (and the Company’s
exploration thereof), and potential future development plans for
Gencaro and rNAPc2, if any. Such statements are based on
management's current expectations and involve risks and
uncertainties. Actual results and performance could differ
materially from those projected in the forward-looking statements
as a result of many factors, including, without limitation, the
risks and uncertainties associated with: ARCA’s financial resources
and whether they will be sufficient to meet its business objectives
and operational requirements; the Company’s ability to complete a
strategic transaction, and the impact of competitive products and
technological changes. These and other factors are identified and
described in more detail in ARCA’s filings with the Securities and
Exchange Commission, including without limitation ARCA’s annual
report on Form 10-K for the year ended December 31, 2021,
and subsequent filings. ARCA disclaims any intent or obligation to
update these forward-looking statements.
Investor & Media
Contact:Derek Cole720.940.2163derek.cole@arcabio.com
ARCA Biopharma (NASDAQ:ABIO)
Historical Stock Chart
From Jul 2024 to Aug 2024
ARCA Biopharma (NASDAQ:ABIO)
Historical Stock Chart
From Aug 2023 to Aug 2024